GB0118419D0 — Improvements relating to injection devices
Assigned to Owen Mumford Ltd · Expires 2001-09-19 · 25y expired
What this patent protects
An injection device for a syringe incorporates housing for a syringe. A needle shroud is captive to the leading end of the housing and is movable before use between extended and retracted positions. A drive member is releasable from a rearward position within the housing to urge …
USPTO Abstract
An injection device for a syringe incorporates housing for a syringe. A needle shroud is captive to the leading end of the housing and is movable before use between extended and retracted positions. A drive member is releasable from a rearward position within the housing to urge the syringe forwards to project its needle beyond the retracted needle shroud and then to express a dose through the needle. Locating members on the housing capture the drive member at its forward position (attained after expressing the dose). The captured drive member is also arranged to block retraction of the needle shroud from its extended position.
Drugs covered by this patent
- naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.